Review of NICE Technology Appraisal Guidance No. 239; Fulvestrant for the treatment of locally advanced or metastatic breast cancer

The Institute was proposing that TA239 should be added to the ‘static guidance list’.

Some comments received during consultation with Consultees and Commentators disagreed with the recommendation to move TA239 to the static list, but the evidence supplied was similar to that which was originally considered by the Committee during the development of TA239, and as such is unlikely to lead to a change in the existing recommendations.

After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

Consequently, TA239 will be moved to the ‘static guidance list’. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

November 2014

Attachments

Appendix A – Decision paper presented to the Institute’s Guidance Executive